RCUS
Arcus Biosciences Inc
25.10$
-5.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -196.9% | -283.9% | -1.4% | -241.0% | 54.2% | -384.6% | -471.4% | -83.1% | -373.1% | -363.6% | -811.8% | -290.2% | -405.1% | |
| 3.1% | 9.7% | 2.1% | 5.1% | 4.2% | 11.5% | 10.7% | 1.3% | 7.7% | 9.1% | 11.8% | 7.3% | 8.5% | |
| 56.3% | 58.1% | 13.8% | 51.3% | 39.6% | 65.4% | 57.1% | 9.4% | 53.8% | 45.5% | 111.8% | 36.6% | 53.8% | |
| 50.0% | – | – | – | – | – | – | – | – | – | – | – | – | |
| -28.1% | -77.4% | -25.5% | -48.7% | 210.4% | -88.5% | -132.1% | -92.5% | 80.8% | -90.9% | -182.4% | -114.6% | -74.4% | |
| 31.3% | 19.4% | 2.8% | 0.0% | 2.1% | 3.8% | 3.6% | 0.0% | 0.0% | 3.0% | 0.0% | 0.0% | 0.9% | |
| 34.4% | 90.3% | -116.6% | 161.5% | -60.4% | 196.2% | 114.3% | 85.6% | 303.8% | -551.5% | 670.6% | 126.8% | 53.8% | |
| – | – | – | -2.6% | 2.1% | – | – | – | – | – | – | – | – | |
| – | – | – | – | 97.9% | 0.0% | – | – | 0.0% | 0.0% | – | – | – | |
| 18.8% | 9.7% | 157.9% | 5.1% | 100.0% | -7.7% | 507.1% | 32.5% | 30.8% | 866.7% | 17.6% | 39.0% | 267.5% | |
| -143.8% | -183.9% | 40.0% | -74.4% | 93.8% | -196.2% | 150.0% | 35.0% | -38.5% | -48.5% | -123.5% | -124.4% | -83.8% | |
| -228.1% | -303.2% | -4.1% | -241.0% | 52.1% | -388.5% | -475.0% | -83.1% | -373.1% | -366.7% | -811.8% | -290.2% | -406.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.